Abbott Labs Files 8-K on Financials
Ticker: ABT · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1800
| Field | Detail |
|---|---|
| Company | Abbott Laboratories (ABT) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ABT
TL;DR
Abbott Labs filed an 8-K for financial updates, nothing major in this snippet.
AI Summary
On October 15, 2025, Abbott Laboratories filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or new operational details were disclosed in the provided excerpt.
Why It Matters
This filing indicates Abbott Laboratories is providing updates on its financial performance and condition to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing for financial reporting and does not indicate any immediate or significant risks.
Key Players & Entities
- ABBOTT LABORATORIES (company) — Registrant
- October 15, 2025 (date) — Date of Report
- Illinois (location) — State of Incorporation
- 36-0698440 (organization_id) — IRS Employer Identification No.
- 100 Abbott Park Road (address) — Principal executive offices
- Abbott Park (location) — City of principal executive offices
- 60064-6400 (postal_code) — Zip code of principal executive offices
- ( 224 ) 667-6100 (phone_number) — Registrant's telephone number
FAQ
What specific financial results or conditions are being reported by Abbott Laboratories in this 8-K filing?
The provided excerpt states the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific results or conditions.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 15, 2025.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Abbott Laboratories' state of incorporation and IRS Employer Identification Number?
Abbott Laboratories is incorporated in Illinois and its IRS Employer Identification Number is 36-0698440.
Where are Abbott Laboratories' principal executive offices located?
Abbott Laboratories' principal executive offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.
Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 14.4 · Accepted 2025-10-15 07:33:48
Filing Documents
- abt-20251015.htm (8-K) — 27KB
- abt-2025q3xexhibitx991.htm (EX-99.1) — 656KB
- abbottlogo.jpg (GRAPHIC) — 7KB
- 0001628280-25-045049.txt ( ) — 876KB
- abt-20251015.xsd (EX-101.SCH) — 2KB
- abt-20251015_def.xml (EX-101.DEF) — 15KB
- abt-20251015_lab.xml (EX-101.LAB) — 26KB
- abt-20251015_pre.xml (EX-101.PRE) — 16KB
- abt-20251015_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On October 15, 2025, Abbott Laboratories announced its results of operations for the third quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Exhibit 99.1 Press Release dated October 15, 2025 (furnished pursuant to Item 2.02). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: October 15, 2025 By: /s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer